Amgen Statement on January 9, 2017, U.S. District Court Decision
January 09 2017 - 6:21PM
PR Newswire (US)
THOUSAND OAKS,
Calif., Jan. 9, 2017
/PRNewswire/ -- Amgen (NASDAQ:AMGN) issued the following
statement regarding the U.S. District Court of Delaware's denial of Sanofi and Regeneron's
motion to stay the injunction pending the appeal in the ongoing
PCSK9 patent litigation:
Today, the U.S. District Court of Delaware denied Sanofi and Regeneron's motion
to stay the injunction pending the appeal in the ongoing PCSK9
patent litigation. By this ruling, the Court has extended the time
before the injunction will be imposed by 15 days (from 30 days to
45 days) to allow Sanofi and Regeneron to seek appellate review of
the Court's orders on injunction and denial of stay pending
appeal.
Amgen respects the court's thoughtful deliberations in a
situation where a competitor made the choice to launch at risk
during the pendency of a patent lawsuit within months of an
expedited trial date. The Company remains confident in the
validity of its patents.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-statement-on-january-9-2017-us-district-court-decision-300388202.html
SOURCE Amgen
Copyright 2017 PR Newswire
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024